Denosumab Therapy in CKD Stage 4 Patients

Introduction to Denosumab

• The American College of Rheumatology conditionally recommends denosumab for solid organ transplant recipients with eGFR ≥35 mL/min, and KDIGO guidelines support its use even in more advanced CKD with appropriate monitoring 1, 2

Why Bisphosphonates Cannot Be Used

• Bisphosphonates are absolutely contraindicated when eGFR <35 mL/min due to lack of safety data and risk of accumulation in bone and soft tissues 2

Why Denosumab is the Optimal Choice

• Denosumab does not require dose adjustment for renal function and can be safely used across all stages of CKD, including dialysis patients 1, 3
• Unlike bisphosphonates, denosumab is not renally excreted and does not accumulate in patients with kidney disease 1, 3

Mandatory Pre-Treatment Requirements

• Measure intact PTH, serum calcium, phosphorus, 25(OH) vitamin D, and 1,25(OH)₂ vitamin D to evaluate for CKD-mineral and bone disorder (CKD-MBD) 1, 4
• Correct any hypocalcemia before the first dose, as this is an FDA-mandated absolute requirement 1, 3
• Obtain baseline dental evaluation to prevent osteonecrosis of the jaw 1, 3

Essential Supplementation Protocol

• Calcium supplementation: 1,000-1,500 mg daily 1, 3
• Activated vitamin D (calcitriol, paricalcitol, or doxercalciferol) is required, as patients with eGFR <30 cannot adequately convert cholecalciferol or ergocalciferol to active forms 1

Intensive Monitoring Protocol

• Check serum calcium and phosphorus at least monthly for the first 3 months, then every 3 months 1
• Monitor PTH every 3 months for the first 6 months, then every 3 months thereafter 1
• Measure serum calcium immediately before each denosumab injection (every 6 months) 1, 3
• The incidence of hypocalcemia reaches 25.5% in patients with advanced CKD receiving denosumab, with severe symptomatic cases typically occurring 4-35 days after administration 1, 3

Critical Safety Considerations

• Never discontinue denosumab abruptly, as its reversible mechanism of action leads to rebound bone resorption and increased fracture risk within months of stopping 1, 3
• Ensure PTH is not severely elevated (>800 pg/mL) before starting denosumab, as this suggests predominant renal osteodystrophy rather than osteoporosis 4

Why Other Agents Are Not Appropriate

• Teriparatide/PTH analogs: Off-label use in CKD stage 4-5 with no established safety or efficacy data; causes hypercalcemia which is particularly problematic in CKD-MBD 1, 4
• Romosozumab: Conditionally recommended AGAINST in solid organ transplant recipients due to potential harms 2